4,136 results on '"Offidani A"'
Search Results
152. Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents
153. Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
154. Achievement and maintenance of therapeutic response to brodalumab in patients with moderate‐to‐severe plaque psoriasis: An Italian, observational, retrospective and prospective study (BRIGHT study).
155. Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment.
156. InflammamiR-146a and -155 Plasma Levels are Associated with Clinical Efficacy of Risankizumab Treatment in Psoriatic Patients: Pilot Study
157. Belantamab Mafodotin: From Clinical Trials Data to Real Life Experiences
158. 'It unleashed all the worries we tried to calm down': The Trump administration's impact on the mental health of immigrant communities
159. Solar-driven valorization of glycerol towards production of chemicals and hydrogen
160. Colistin enhances therapeutic efficacy of daptomycin or teicoplanin in a murine model of multiresistant Acinetobacter baumannii sepsis
161. Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations
162. Hidradenitis suppurativa and adalimumab in the COVID-19 era
163. Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)
164. Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis
165. Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease
166. Correlation between immunohistochemical staining of CEACAM1 and clinicopathological findings in oral pre-neoplastic lesions and squamous cell carcinoma
167. Carfilzomib and Lenalidomide for the Treatment of Primary Plasma Cell Leukemia: Final Results of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged ≥66 Years
168. Long Term Survival in Multiple Myeloma Patients: A Multicenter Italian Experience
169. Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years
170. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
171. Supplementary Figure S2 from Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients
172. TRIPOD Checklist from Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients
173. Supplementary Figure 4 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia
174. Supplementary Figure 4 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome
175. Supplementary Figure 3 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome
176. Supplementary Table 2 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia
177. Supplementary Figure 2 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome
178. Supplementary Figure 1 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia
179. Supplementary Table 3 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome
180. Supplementary Appendix from Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients
181. Supplementary Table 1 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia
182. The Role of Diet in Children with Psoriasis: Emerging Evidence and Current Issues
183. Supplementary Table 2 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome
184. Supplementary Table 1 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome
185. Supplementary Methods from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia
186. Supplementary Figure 1 from Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome
187. Supplementary Figure 5 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia
188. Supplementary Figure 2 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia
189. Supplementary Figure 3 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia
190. Prevalence and Antifungal Susceptibility of Vaginal Yeasts in Outpatients Attending a Gynecological Center in Ancona, Italy
191. Vitiligo, from Pathogenesis to Therapeutic Advances: State of the Art
192. Efficacy and Safety of Botulinum Toxin B in Focal Hyperhidrosis: A Narrative Review
193. Oral oxybutynin chloride therapy in the management of hidradenitis suppurativa: A prospective study
194. The Impact of Treatment with IL-17/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients with Plaque Psoriasis and/or Psoriatic Arthritis: A Systematic Review
195. Experts’ consensus on the definition and management of high risk multiple myeloma
196. Real‐world assessment of treatment patterns and outcomes in patients with relapsed‐refractory multiple myeloma in an Italian haematological tertiary care centre
197. Dataset of Clinical Cases, Images, Image Labels and Captions from Open Access Case Reports from Pubmed Central
198. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
199. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study
200. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.